However, he also points out that sharp corrections are creating opportunities for long-term investors, adding, “Valuations are correcting sharply. Anyone with cash will be king. The next few weeks could offer a brilliant chance to invest — but stagger your buying.”
Despite recent underperformance, financial stocks could play a pivotal role in any market recovery. Vora maintains that “if the market moves, it cannot move without financials,” and suggests that a quick resolution to current uncertainties could revive the sector’s leadership. At the same time, he cautions that prolonged stress may hit smaller businesses first, saying, “If it prolongs, you could see pain in MSMEs and small businesses, which can trigger a broader cycle.”
The outlook for consumption, too, hinges on how long the current disruption lasts. While near-term pressures from rising oil prices may weigh on demand, the structural story remains intact for now, with Vora observing, “If this lasts long, there can be medium-term damage to consumption. If it resolves soon, the theme remains intact.”
On the earnings front, early warning signs are beginning to emerge. While the economy showed resilience prior to the geopolitical flare-up, expectations may begin to soften if uncertainty persists. “Some downgrades will happen. Expectations could deteriorate if the situation elongates,” he notes. The stress, he believes, will first be visible at the bottom of the pyramid, with “the first pain” likely to be felt in MSMEs, small businesses, and the retail segment, where resilience is weakest. He also highlights potential second-order effects, adding, “You could see issues in fertiliser procurement and farming — there are many moving parts.”
In such a fast-moving environment, Vora advocates flexibility in investment strategy, particularly for mutual fund investors. “A flexicap approach makes sense. The fund manager can adjust allocations, which is difficult for investors to do quickly,” he says. Sectorally, opportunities remain selective. In pharmaceuticals, intense competition in the diabetes drug space is raising questions about profitability, prompting a shift toward ancillary plays. “There are many competitors, so profitability remains to be seen. Ancillary plays could be interesting,” he explains. Meanwhile, in IT, although structural growth concerns persist, recent corrections may have created tactical opportunities. “Structurally, it is a low-growth sector now, but the recent correction may be a bit overdone,” he says, adding, “With stocks down 30–35% in some cases, it may be time to bottom fish a bit. It is more of a value and defensive play.”In essence, the current market environment calls for patience, discipline, and preparedness. Rather than rushing into decisions, investors may benefit from conserving capital, staying flexible, and positioning themselves to act when clarity begins to return.
